These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25385110)

  • 1. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
    Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
    Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
    Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
    AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Feng M; Falgueyret JP; Tawa P; Witmer M; DiStefano D; Li Y; Burch J; Sachs N; Lu M; Cauchon E; Campeau LC; Grobler J; Yan Y; Ducharme Y; Côté B; Asante-Appiah E; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2014; 58(3):1652-63. PubMed ID: 24379202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.
    Lu M; Felock PJ; Munshi V; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Gomez R; Anthony NJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3324-35. PubMed ID: 22391531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
    Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
    Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
    Côté B; Burch JD; Asante-Appiah E; Bayly C; Bédard L; Blouin M; Campeau LC; Cauchon E; Chan M; Chefson A; Coulombe N; Cromlish W; Debnath S; Deschênes D; Dupont-Gaudet K; Falgueyret JP; Forget R; Gagné S; Gauvreau D; Girardin M; Guiral S; Langlois E; Li CS; Nguyen N; Papp R; Plamondon S; Roy A; Roy S; Seliniotakis R; St-Onge M; Ouellet S; Tawa P; Truchon JF; Vacca J; Wrona M; Yan Y; Ducharme Y
    Bioorg Med Chem Lett; 2014 Feb; 24(3):917-22. PubMed ID: 24412110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
    Zhang Z; Xu W; Koh YH; Shim JH; Girardet JL; Yeh LT; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2007 Feb; 51(2):429-37. PubMed ID: 17116677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.